



UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
REGION IV  
611 RYAN PLAZA DRIVE, SUITE 400  
ARLINGTON, TEXAS 76011-4005

November 9, 2007

Alaska Heart Institute, LLC  
ATTN: Baxter Burton  
Chief Executive Officer  
3260 Providence Drive, Suite 537  
Anchorage, AK 99508

SUBJECT: LICENSE AMENDMENT

Please find enclosed Amendment No. 14 to License No. 50-29111-01 **naming Mark A. Selland, M.D. as Radiation Safety Officer**. An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14)(iv). You should review this license carefully and be sure that you understand all conditions. If you have any questions, please contact me at 817-860-8189.

NRC expects licensees to conduct their programs with meticulous attention to detail and a high standard of compliance. Because of the serious consequences to employees and the public that can result from failure to comply with NRC requirements, you must conduct your radiation safety program according to the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate by NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers: Inspection and Investigations," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC in writing of any change in mailing address.
3. By 10 CFR 30.36(d) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:
  - a. When you decide to terminate all activities involving materials authorized under the license whether at the entire site or any separate building or outdoor area; or
  - b. If you decide not to acquire or possess and use authorized material; or
  - c. When no principal activities under the license have been conducted for a period of 24 months.
4. In accordance with 10 CFR 35.14, notify the NRC no later than 30 days after:
  - a. The date that the licensee permits an individual to work as an authorized user, an authorized nuclear pharmacist or an authorized medical physicist under 10 CFR 35.13(b)(1) through (b)(4);

- b. An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, or an authorized medical physicist permanently discontinues duties under the license or has a name change;
  - c. The licensee's mailing address changes;
  - d. The licensee's name changes, but the name change does not constitute a transfer of control of the license as described in 10 CFR 30.34(b); or
  - e. The licensee has added to or changed the areas of use identified in the application or on the license where byproduct material is used in accordance with either 35.100 or 35.200.
5. Request and obtain a license amendment before you:
- a. Change Radiation Safety Officers;
  - b. Order byproduct material in excess of the amount, radionuclide or form authorized on the license;
  - c. Add or change the areas or address(es) of use identified in the license application or on the license, except for areas of use where byproduct material is used only in accordance with either 10 CFR 35.100 or 35.200; or
  - d. Change the name or ownership of your organization.

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter and its enclosure will be available electronically for public inspection in the NRC Public Document Room or from the NRC's document system (ADAMS). ADAMS is accessible from the NRC Web site at <http://www.nrc.gov/reading-rm/adams.html>.

Thank you for your cooperation.

Sincerely,

**/RA/**

Roberto J. Torres, Senior Health Physicist  
Nuclear Materials Safety, Branch B

Docket: 030-34474  
License: 50-29111-01  
Control: 471492

Enclosure: As stated

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee  1. Alaska Heart Institute, LLC  2. 3260 Providence Drive, Suite 537 Anchorage, Alaska 99508	In accordance with letter dated August 23, 2007  3. License number 50-29111-01 is amended in its entirety to read as follows:  4. Expiration date September 30, 2012  5. Docket No. 030-34474 Reference No.
--	---

- |   |   |  |
|---|---|--|
| 6. Byproduct, source, and/or special nuclear material<br><br>A. Any byproduct material permitted by 10 CFR 35.100<br><br>B. Any byproduct material permitted by 10 CFR 35.200 | 7. Chemical and/or physical form<br><br>A. Any<br><br>B. Any, except generators | 8. Maximum amount that licensee may possess at any one time under this license<br><br>A. As needed<br><br>B. As needed |
|---|---|--|

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
  - B. Any imaging and localization study permitted by 10 CFR 35.200.

**CONDITIONS**

- 10. Licensed material may be used or stored only at the licensee's facilities located at:
  - A. 3841 Piper Street, Suite T1-057, Anchorage, Alaska
  - B. 2490 South Woodworth Loop, Suite 250, Palmer, Alaska
- 11. The Radiation Safety Officer for this license is Mark A. Selland, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user and/or authorized nuclear pharmacist in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for the materials and uses indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Mark A. Selland, M.D.	35.200
Mario Binder, M.D.	35.200
Alan E. Skolnick, M.D.	35.200

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
50-29111-01

Docket or Reference Number  
030-34474

Amendment No. 14

Authorized Users

Material and Use

Julee K. Holyater, M.D.	35.100 and 35.200
Bradley K. Cruz, M.D.	35.100 and 35.200
Lester B. Lewis, M.D.	35.100 and 35.200
Lawrence P. Wood, M.D.	35.100 and 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated as May 10, 2002 (ML021650625)
- B. Facsimile dated September 5, 2002 (ML023190125)
- C. Letter dated January 15, 2004 (ML040300874)
- D. Letter dated February 8, 2006 (ML060610684)
- E. Letter dated March 14, 2006 (ML060880150)
- F. Letter dated June 1, 2006 (ML061840532)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: November 9, 2007

By: /RA/  
Roberto J. Torres, Senior Health Physicist  
Nuclear Materials Safety, Branch B  
Region IV  
Arlington, Texas 76011